Afficher la couverture 'An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations | Chouaid, Christos' en grand format
/5

0 avis

An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Archive ouverte

Chouaid, Christos | Bosquet, Lise | Girard, Nicolas | Kron, Anna | Scheffler, Matthias | Griesinger, Frank | Sebastian, Martin | Trigo, Jose | Viteri, Santiago | Knott, Craig | Rodrigues, Bernardo | Rahhali, Nora | Cabrieto, Jedelyn | Diels, Joris | Perualila, Nolen, J | Schioppa, Claudio, A | Sermon, Jan | Toueg, Raphael | Erdmann, Nicole | Mielke, Janka | Nematian-Samani, Mehregan | Martin-Fernandez, Cristina | Pfaira, Innocent | Li, Tracy | Mahadevia, Parthiv | Wolf, Jürgen

Edité par CCSD ; Springer Verlag (Germany) -

International audience. Introduction: Patients with advanced, epidermal growth factor receptor (EGFR)-mutated, non-small cell lung cancer (NSCLC) with Exon 20 insertion mutations (Exon20ins) have poor prognoses, exacerbated by a previous lack of specific treatment guidelines and unmet need for targeted therapies. Amivantamab, an EGFR and MET bispecific antibody, demonstrated efficacy and tolerability in patients with advanced EGFR-mutated NSCLC with Exo-n20ins following platinum-based therapy in CHRYSALIS (NCT02609776; Cohort D?). Since CHRYSALIS was single-arm, individual patient

Suggestions

Du même auteur

Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis

Archive ouverte | van Sanden, Suzy | CCSD

International audience. Background Information on the epidemiology of uncommon EGFR mutations including exon 20 insertions amongst nonsmall-cell lung cancer (NSCLC) is lacking. Objective The objective of this pragma...

Amivantamab Compared with Real-World Physician’s Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations

Archive ouverte | Christopoulos, Petros D. | CCSD

International audience. Patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor gene (EGFR) Exon 20 insertions (Exon20ins) at the second line and beyond (2L+) have an unmet ne...

Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany

Archive ouverte | Griesinger, Frank | CCSD

International audience. Objectives: To describe the impact of immune checkpoint inhibitors (ICIs) on treatment patterns and survival outcomes in patients with locally advanced or metastatic non-small cell lung cance...

Chargement des enrichissements...